SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses that Dave & Buster's Entertainment issued a press release on June 15, 2026 announcing "results its first quarter 2026 results," with the press release attached as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance information.
View raw filing on EDGAR →NextNav announced a redemption of all outstanding 5.00% Senior Secured Convertible Notes due 2028 at 100% of principal plus accrued interest, with a redemption date of June 25, 2026. This is a material debt management and capital structure event affecting the company's liquidity position and financial obligations.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the certified results of Sprinklr's annual meeting of stockholders held on June 11, 2026. The filing presents voting outcomes for three proposals: (1) election of Stephen M. Ward, Jr. as a Class II director, (2) advisory approval of named executive officer compensation, and (3) ratification of KPMG LLP as independent auditor. All three matters are material governance events that affect investor understanding of board composition, executive compensation oversight, and audit firm selection.
View raw filing on EDGAR →Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This is a material product launch in the oncology segment with 180-day generic drug exclusivity, targeting a market with approximately $253.8 million in annual sales for the branded equivalent. The disclosure is a strategic operational milestone—a new product commercialization—rather than a discrete financial event (earnings, debt, M&A) or governance matter, making it operational_other.
View raw filing on EDGAR →The filing discloses resolution of a material delisting risk. Northann Corp. received a non-compliance notice from NYSE American on December 8, 2025 for failing to meet continued listing standards under Section 1003(a)(i) of the Company Guide. The company subsequently regained compliance on June 10, 2026, after demonstrating compliance for two consecutive quarters, resulting in removal from the noncompliant issuers list. This is a material event affecting the registrant's listing status and investor confidence.
View raw filing on EDGAR →The Company issued a press release on June 15, 2026 announcing Phase 2 clinical trial results for ELI-002 7P in pancreatic cancer and outlining a refined Phase 3 development strategy. While this is clinical trial data rather than financial earnings, it is a material disclosure of significant clinical progress that would affect investor assessment of the Company's pipeline and development trajectory. The attachment of a press release and conference call presentation indicates this is a formal material announcement comparable in disclosure significance to an earnings release.
View raw filing on EDGAR →Talen Energy completed a material acquisition under a Merger Agreement, with the acquired companies becoming wholly owned subsidiaries. The transaction involved approximately $2.55 billion in cash consideration plus 2.399998 million shares of stock, funded by senior unsecured notes issued in April 2026.
View raw filing on EDGAR →Talen Energy entered into a Seventh Amendment to its Credit Agreement, which increased revolving facilities from $900 million to $1.35 billion and extended maturity. The amendment's effectiveness was conditioned on substantially concurrent consummation of the acquisition.
View raw filing on EDGAR →The filing discloses a board decision to maintain the dividend rate on SATA Stock at 13.00% per annum and declares specific daily cash dividends for July 2026. While dividend declarations are routine for established dividend-paying securities, the 13% annual rate and the explicit tax guidance stating the company has no accumulated or current earnings and profits—and does not expect to generate earnings in the foreseeable future—signals that these are return-of-capital distributions rather than earnings-based dividends. This tax characterization and the forward guidance about absent profitability would be material to investors assessing the sustainability and nature of the distribution stream.
View raw filing on EDGAR →Enhanced Group Inc. entered into a securities purchase agreement on June 14, 2026, to issue 12,853,468 shares of Class A common stock and accompanying warrants for approximately $50 million in gross proceeds. The private placement, which requires stockholder approval due to potential dilution exceeding 19.99% of outstanding shares, was announced via press release and includes anti-dilution adjustments for 24 months.
View raw filing on EDGAR →Enhanced Group Inc. terminated a material debt instrument (the Note) through repayment using proceeds from the securities purchase agreement closing expected June 17, 2026, thereby eliminating a financing obligation and materially affecting the registrant's capital structure.
View raw filing on EDGAR →The controlling stockholder approved via written consent a material private placement involving dilutive issuances exceeding 19.99% of outstanding shares, securities to related parties, and securities to the CEO, materially affecting voting power and ownership structure.
View raw filing on EDGAR →Strive announced a significant bitcoin purchase of 73 BTC at ~$63,646 per coin during June 8-14, 2026, along with updates to its treasury holdings including cash, bitcoin, and STRC Stock positions. While this reflects the company's stated bitcoin treasury strategy, the disclosure does not fit neatly into standard 8-K event categories (not M&A, not a restatement, not an impairment, not a covenant breach). The material bitcoin acquisition and updated asset position warrant disclosure as a material corporate event affecting investor assessment of the company's financial posture and strategy execution.
View raw filing on EDGAR →Context Therapeutics announced positive interim efficacy and safety results from a Phase 1 clinical trial for CTIM-76, a bispecific antibody candidate, disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →Mari J. Baker, a director and Chair of the Executive Compensation and Development Committee, notified the Board on June 10, 2026 of her intent not to stand for reelection at the September 24, 2026 Annual Meeting, completing her 15-year tenure. This is a material departure of a senior board member with significant committee leadership responsibilities, affecting board composition and governance structure.
View raw filing on EDGAR →This Item 8.01 disclosure provides a comprehensive NAV update as of May 31, 2026, including detailed valuation methodologies, property portfolio metrics (55 properties, 95% leased, 30% levered), June 2026 distribution declarations, and disclosure of a recent acquisition (Junction One, £50.0 million / $66.7 million retail property in Liverpool acquired May 15, 2026). While NAV updates are routine for non-traded REITs, the combination of material portfolio information, distribution details, and acquisition disclosure makes this material to investors assessing the registrant's financial position and asset base. The event does not fit neatly into more specific categories (not earnings, not M&A alone, not compensation), warranting classification as other_material.
View raw filing on EDGAR →Allbirds completed the sale of its entire footwear business, including intellectual property, inventory, and customer lists, to Allbirds IP LLC for $40.7 million in cash on June 9, 2026.
View raw filing on EDGAR →Allbirds announced a special dividend to stockholders funded by proceeds from the asset sale, with a record date of June 25, 2026 and payment within 60 days.
View raw filing on EDGAR →The disclosure centers on amendments to Adam K. Bowen's compensatory and employment arrangements as Interim CFO, including modifications to base salary, bonus structure, discretionary cash awards ($100,000 initial plus conditional quarterly awards), and LTI equity vesting terms. While the filing is under Item 5.02, the substantive focus is on compensation modifications rather than a departure or appointment event, making exec_compensation the most precise classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Kodiak AI's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports final voting tallies for two proposals: election of two Class I directors (Don Burnette and Kristin Sverchek) and ratification of Deloitte & Touche LLP as independent auditor. This is a textbook Item 5.07 disclosure of shareholder vote results, which is material to investors as it confirms governance outcomes and auditor appointment.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from NewtekOne's Annual Meeting of Shareholders held on June 12, 2026. The filing reports voting outcomes for three proposals: election of two directors (Proposal I), ratification of RSM US LLP as independent auditors (Proposal II), and advisory approval of named executive officer compensation (Proposal III), with detailed vote tallies for each. This is a quintessential Item 5.07 disclosure and is material to investors as it reflects shareholder governance decisions.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Alliance Laundry Holdings' June 11, 2026 annual meeting, covering four proposals: election of Class I directors, ratification of Ernst & Young LLP as independent auditor, advisory vote on compensation vote frequency, and advisory vote on named executive officer compensation. The filing presents final vote tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Zoom's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting results for three proposals: election of Class I directors (Eric S. Yuan and Lieut. Gen. H.R. McMaster), ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The detailed vote tallies (FOR, AGAINST, ABSTAIN, BROKER NON-VOTE) are the core disclosure required by Item 5.07.
View raw filing on EDGAR →Rhythm Pharmaceuticals disclosed interim Phase 2 trial data for setmelanotide in Prader-Willi syndrome and other obesity-related indications, along with multiple clinical data presentations at the Endocrine Society's Annual Meeting (ENDO 2026), including efficacy and safety results showing BMI reductions and improvements in hyperphagia. This material clinical development milestone affects investor assessment of the company's pipeline and commercial prospects but does not fit the standard 8-K event taxonomy.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Verde Clean Fuels' 2026 Annual Meeting held on June 12, 2026. The filing reports voting outcomes for two proposals: (1) re-election of Jonathan Siegler as Class III director with 38,174,994 votes for and 337,358 withheld, and (2) ratification of Deloitte & Touche LLP as independent auditor with 40,205,518 votes for and 5,701 against. These are routine but material governance matters that affect board composition and audit oversight.
View raw filing on EDGAR →The filing discloses financial results for the fiscal quarter and year ended April 30, 2026 via a press release attached as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly and annual financial performance information.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 10, 2026 Annual General Meeting under Item 5.07. The filing reports detailed vote tallies for four proposals: election of seven directors, advisory vote on executive compensation, frequency of advisory compensation votes (approved as annual), and appointment of Grant Thornton LLP as auditor. All material proposals were approved by shareholders.
View raw filing on EDGAR →This Item 8.01 disclosure provides a comprehensive NAV update as of May 31, 2026, showing NAV per share of $8.1908 (up from $8.1640 in April), along with detailed portfolio composition, leverage metrics (31.9%), capital raising activity ($286.6 million quarter-to-date), and updated suitability standards for Washington investors. While NAV updates are routine for non-traded REITs, the material portfolio and valuation information—including sensitivity analyses on cap rates and discount rates—would affect a reasonable investor's assessment of the fund's value and performance. The disclosure does not fit neatly into more specific categories (not earnings, not M&A, not impairment), making "other_material" the appropriate classification.
View raw filing on EDGAR →Mr. Pascal Desroches was appointed as an Independent Director and Audit Committee chair of Honeywell Aerospace Inc., effective June 14, 2026, a material governance change affecting board composition and oversight.
View raw filing on EDGAR →Honeywell completed the spin-off of its Aerospace Technologies business into an independent, publicly traded company with a distribution ratio of 1 share for every 2 Honeywell shares, scheduled for distribution on June 29, 2026, and listing on Nasdaq under ticker 'HONA'.
View raw filing on EDGAR →Eva Boratto, a Board member of UPS, resigned effective immediately on June 13, 2026, due to her appointment as CFO of Cencora, Inc. This is a clear executive departure—a director leaving the Board. Board composition changes are material to investors as they affect governance and oversight. The resignation was not due to disagreement, but the departure itself is the salient disclosed event.
View raw filing on EDGAR →This Item 8.01 disclosure provides a comprehensive NAV update as of May 31, 2026, showing Aggregate Fund NAV of $5,091,114 thousand and NAV per Fund Interest of $13.2898, along with portfolio metrics (276 industrial buildings, 58.4 million square feet, 89.4% occupied) and leverage ratio of 45.1%. While NAV updates are routine for non-traded REITs, this filing includes material portfolio and financial information that would affect investor assessment of the fund's value and performance, including capital raised ($89.8 million quarter-to-date) and redemptions ($54.1 million). The disclosure does not fit neatly into more specific event categories (not earnings, not M&A, not impairment, not going-concern), making "other_material" the appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Rockwell Medical's June 12, 2026 Annual Meeting of Stockholders. The filing presents voting tallies for four proposals: election of Class II directors (Joseph Dawson and Joan Lau, Ph.D.), advisory approval of named executive officer compensation, ratification of EisnerAmper LLP as independent auditor, and approval of a reverse stock split amendment. The materiality is high given the reverse stock split approval and auditor ratification are substantive corporate governance matters affecting investors.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 11, 2026 Annual Meeting of Stockholders, filed under Item 5.07. The filing reports final voting tallies for Proposal 1 (election of three Class I directors) and Proposal 2 (ratification of Deloitte & Touche LLP as independent auditor), with specific vote counts for each nominee and proposal. Annual meeting voting results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →The filing discloses financial results for Vistagen's fiscal year ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance and condition.
View raw filing on EDGAR →Essential Properties Realty Trust closed a $400 million underwritten public offering of senior notes on June 15, 2026, governed by an indenture with Wells Fargo Securities and BofA Securities as underwriter representatives. The offering represents a material capital structure transaction involving entry into definitive debt agreements.
View raw filing on EDGAR →Conversion of approximately 103 million shares of Series Preferred Stock into Class A and Class B common stock in connection with the Company's IPO closing on June 15, 2026, representing a material dilutive event that fundamentally alters the capital structure.
View raw filing on EDGAR →Material modification to rights of security holders and amendments to the Certificate of Formation and Bylaws in connection with the Company's IPO completion on June 15, 2026, reflecting the transition from private to public company status and governance restructuring.
View raw filing on EDGAR →Adoption of amended and restated equity incentive plans (the A&R 2024 Plan and Second A&R ESPP) in connection with the Company's IPO, establishing the framework for compensatory equity awards to directors, officers, and employees with hundreds of millions of shares reserved.
View raw filing on EDGAR →Completion of a major IPO on June 15, 2026, involving 638.9 million shares at $135 per share, raising substantial capital for growth initiatives and representing a transformational capital-raising event.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 11, 2026 annual meeting of stockholders, covering three proposals: election of five directors, ratification of auditor Baker Tilly US, LLP, and advisory approval of named executive officer compensation. The filing presents the vote tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Sweetgreen's Annual Meeting of Stockholders held on June 11, 2026. The filing reports the final voting tallies for three proposals: (1) election of nine directors, (2) ratification of Deloitte & Touche LLP as independent auditor, and (3) advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, and the disclosure includes detailed vote counts (FOR, AGAINST/WITHHOLD, ABSTAIN, and BROKER NON-VOTES) for each proposal, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →Cushman & Wakefield amended its credit agreement affecting approximately $848 million in outstanding term loans, including repricing, a seven-year maturity extension to 2033, and a $353 million upsizing. Concurrently, the company completed a partial redemption of $350 million of its 6.750% Senior Secured Notes due 2028, reducing outstanding principal from $550 million to $200 million.
View raw filing on EDGAR →Spyre Therapeutics announced positive Phase 2 SKYLINE trial topline results for SPY002 in ulcerative colitis, meeting the primary endpoint with a statistically significant 10.7-point RHI reduction (p<0.0001) and demonstrating a favorable safety profile. This material clinical milestone represents a significant development in the company's pipeline that would affect investor assessment of regulatory prospects and commercial value.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Toast's June 12, 2026 annual meeting of stockholders. The filing presents voting outcomes for three proposals: election of three Class II directors (Kent Bennett, Susan Chapman-Hughes, and Mark Hawkins), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Priority Technology Holdings' 2026 annual meeting of stockholders held on June 11, 2026, including voting outcomes on four proposals: election of six directors, approval of an amendment to the equity incentive plan, advisory vote on executive compensation, and ratification of KPMG LLP as auditor. The filing presents vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →This 6-K discloses FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, based on positive Phase III CAPItello-281 trial results showing a 19% reduction in risk of disease progression or death. This is a material regulatory milestone and product approval event that expands AstraZeneca's oncology portfolio into a second tumor type, representing a significant operational and commercial development rather than a discrete financial, governance, or legal event.
View raw filing on EDGAR →The 6-K discloses HSBC's declaration and payment of a first interim dividend for 2026 of US$0.10 per ordinary share (US$0.50 per ADS), payable on 26 June 2026. This is a routine but material capital distribution to shareholders that would affect investor assessment of capital allocation and shareholder returns.
View raw filing on EDGAR →The filing discloses a press release announcing quarterly financial results for the period ended April 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure, which is material to investors as it provides periodic financial performance information essential to assessing the registrant's financial condition and operating results.
View raw filing on EDGAR →The filing discloses entry into a Vice Chairman Agreement with Mark Iwanowski, appointing him to serve as Vice Chairman in an advisory capacity effective June 12, 2026. Although the position is non-executive and advisory (not a Board seat or officer role under the Exchange Act), the appointment of a high-profile strategic advisor with substantial technology and M&A experience to a named executive-level position is material to investors assessing the company's leadership and strategic direction. The equity compensation structure ($150,000 annual NSOs plus performance-based grants) reinforces the materiality of this appointment.
View raw filing on EDGAR →